94 results
8-K
EX-99.1
IBRX
ImmunityBio Inc
23 Apr 24
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class
6:17am
,” “plans,” “potential,” “predicts,” “indicate,” “projects,” “seeks,” “should,” “will,” “strategy,” and variations of such words or similar expressions
S-3ASR
IBRX
ImmunityBio Inc
17 Apr 24
Automatic shelf registration
5:24pm
the FDA will approve our BLA, if at all.
Our Strategy
We seek to become a leading global immunological therapeutics company by creating next-generation … , the key elements of our strategy include:
advancing the approval and commercialization of our lead IL-15 superagonist antibody-cytokine fusion protein, N
8-K
EX-99.1
7zj0gs9h d9dax
2 Jan 24
ImmunityBio Announces $320 Million Investment by Oberland
6:08am
8-K
EX-99.1
9nusflqp0yizoezy
11 Sep 23
ImmunityBio Announces $470 Million Equity and Debt Financing
6:25am
8-K
tfs 50cs5jvaozigab
1 Sep 23
Other Events
8:30am
8-K
rmqtpe25ap7m
15 Aug 23
Other Events
4:15pm
424B5
pd94tdmk rb
25 Jul 23
Prospectus supplement for primary offering
5:02pm
424B5
e9x577g
24 Jul 23
Prospectus supplement for primary offering
5:12pm
8-K
EX-99.1
czk 9ktrci31p
21 Jul 23
ImmunityBio Announces Execution of $40 Million Equity Financing with Institutional Investors
6:04am
8-K
euafbs
20 Jul 23
Other Events
4:07pm
8-K
zai6hxcod
11 May 23
Other Events
6:45am
8-K
EX-99.1
s3ltzca9rlxjfo
12 Dec 22
ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor
9:07am
424B5
6cy46u
12 Dec 22
Prospectus supplement for primary offering
8:08am